Fresh out of Eli Lil­ly, Christi Shaw sur­faces as Daniel O'­Day's new CEO at CAR-T pi­o­neer Kite

Well, that didn’t take long. 

We found out Thurs­day evening that Christi Shaw has giv­en up her top post as the head of the Bio-Med­i­cines group at Eli Lil­ly for the helm at CAR-T pi­o­neer Kite. New Gilead CEO Daniel O’Day, a Roche vet­er­an, had made find­ing a Kite CEO a top pri­or­i­ty on his ar­rival at Gilead. And he went right for a head­lin­er.

O’Day was clear­ly ex­cit­ed about the coup.

“We con­duct­ed an ex­ten­sive search for a new leader at Kite and we be­lieve that Christi’s unique set of skills will al­low us to con­tin­ue to build on our lead­er­ship po­si­tion in cell ther­a­py,” he said in a pre­pared state­ment. “Christi’s vast ex­pe­ri­ence across com­plex ther­a­peu­tic ar­eas, and par­tic­u­lar­ly in on­col­o­gy, will serve Kite very well. She is clear­ly a leader who will bring teams and in­di­vid­u­als to­geth­er and I am con­fi­dent she will build up­on the en­tre­pre­neur­ial spir­it at Kite as we seek to help more peo­ple with can­cer around the world.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN